452 participants
ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.
- Study Type:
- INTERVENTIONAL
- Last Updated:
- 2023-11-14
- Start Date:
- 2013-05-09
- Completion:
- 2016-07-29
Conditions
- Non-small Cell Lung Cancer With EGFR-Activating Mutations
Interventions
- DRUG